Compare TAC & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TAC | BLLN |
|---|---|---|
| Founded | 1909 | 2016 |
| Country | Canada | United States |
| Employees | 1350 | 713 |
| Industry | Electric Utilities: Central | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.7B |
| IPO Year | N/A | N/A |
| Metric | TAC | BLLN |
|---|---|---|
| Price | $13.48 | $80.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $23.67 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 1.1M | 315.0K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.38% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $45.96 |
| Revenue Next Year | $1.97 | $30.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.34 | $61.96 |
| 52 Week High | $17.88 | $138.70 |
| Indicator | TAC | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 53.55 | 51.64 |
| Support Level | $13.41 | $80.39 |
| Resistance Level | $14.00 | $83.20 |
| Average True Range (ATR) | 0.39 | 6.78 |
| MACD | 0.04 | 0.23 |
| Stochastic Oscillator | 52.29 | 50.20 |
TransAlta Corp is an independent power producer based in Alberta, Canada. The company operates a diverse electrical power generation assets in Canada, the United States, and Western Australia. The company has reportable segments namely, Hydro, Wind & Solar, Gas, Energy Transition segment and Corporate Segment. The company generates the majority of its revenue from the gas segment.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.